A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
A Phase I, Randomized, Single-dose, Crossover, 2-Period, Open-Label Study to Assess the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is a phase I, open-label, randomized, 2-period crossover study with 4-cohorts. All 4 cohorts are independent and non-sequential parts in this study. Each cohort will evaluate 2 formulations (test formulation and reference formulation) of elecoglipron across 2 study treatment periods. Participants within each cohort will be randomized to one of 2 treatment sequences (Test-Reference or Reference-Test).
In total 3 formulations will be evaluated at 2 dose levels each:
- Reference formulation
- Test formulation 1
- Test formulation 2
The study will comprise:
- A Screening Period.
- 2 treatment periods in each cohort - Period 1, and Period 2 during which participants will be admitted to the Clinical Unit and receive a single oral dose of elecoglipron in each period.
- A final Follow-up Visit.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:AstraZeneca Clinical Study Information Center
- 電話番号:1-877-240-9479
- メール:information.center@astrazeneca.com
研究場所
-
-
California
-
Glendale、California、アメリカ、91206
- 募集
- Research Site
-
-
Maryland
-
Brooklyn、Maryland、アメリカ、21225
- 募集
- Research Site
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Healthy participants with suitable veins for cannulation or repeated venipuncture.
- All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
- Females of childbearing potential must not be lactating and if heterosexually active, must agree to use an approved method of highly effective contraception.
- Females of non-childbearing potential must be confirmed at screening visit as postmenopausal or have documentation of irreversible surgical sterilization.
- Sexually active fertile male participants with partners of childbearing potential must adhere to the study specific contraception methods.
- Have a body mass index between 18.5 and 30 kg/m2 inclusive and weigh at least 50 kg.
Exclusion Criteria:
- History of any clinically important disease or disorder.
- History of acute pancreatitis.
- History or presence of gastrointestinal (GI) or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- Clinically significant inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper GI tract.
- Any clinically important illness, medical/surgical procedure, or trauma.
- Participants who have previously received elecoglipron within the last 3 months.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Cohort 1-Treatment Sequence A
Participant will receive a single dose of elecoglipron reference formulation (Dose A) in Period 1 followed by a single dose of elecoglipron test formulation 1 (Dose A) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
|
実験的:Cohort 1 - Treatment Sequence B
Participant will receive a single dose of elecoglipron test formulation 1 (Dose A) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose A) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
|
実験的:Cohort 2 - Treatment Sequence C
Participant will receive a single dose of elecoglipron reference formulation (Dose B) in Period 1 followed by a single dose of elecoglipron test formulation 1 (Dose B) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
|
実験的:Cohort 2 - Treatment Sequence D
Participant will receive a single dose of elecoglipron test formulation 1 (Dose B) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose B) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
|
実験的:Cohort 3 - Treatment Sequence E
Participant will receive a single dose of elecoglipron reference formulation (Dose A) in Period 1 followed by a single dose of elecoglipron test formulation 2 (Dose A) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
|
実験的:Cohort 3 - Treatment Sequence F
Participant will receive a single dose of elecoglipron test formulation 2 (Dose A) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose A) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
|
実験的:Cohort 4 - Treatment Sequence G
Participant will receive a single dose of elecoglipron reference formulation (Dose B) in Period 1 followed by a single dose of elecoglipron test formulation 2 (Dose B) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
|
実験的:Cohort 4 - Treatment Sequence H
Participant will receive a single dose of elecoglipron test formulation 2 (Dose B) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose B) in Period 2.
|
Elecoglipron tablets will be administered orally.
Elecoglipron tablets will be administered orally.
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximum observed drug concentration (Cmax)
時間枠:At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)
時間枠:At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Area under concentration-time curve from time 0 to infinity (AUCinf)
時間枠:At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Time to reach maximum observed concentration (tmax)
時間枠:At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Terminal elimination rate constant (λz)
時間枠:At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Terminal elimination half-life (t1/2λz)
時間枠:At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Apparent total body clearance (CL/F)
時間枠:At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Apparent volume of distribution based on the terminal phase (Vz/F)
時間枠:At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on AUCinf (R AUCinf)
時間枠:At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on AUClast (R AUClast)
時間枠:At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
|
Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on Cmax (R Cmax)
時間枠:At pre-defined intervals from Day 1 to Day 15
|
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
|
At pre-defined intervals from Day 1 to Day 15
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of participants with adverse events (AEs)
時間枠:From screening (Day -28) up to follow-up visit (Day 18-Day 22)
|
To assess the safety and tolerability of different formulations of elecoglipron following single oral administration in healthy participants.
|
From screening (Day -28) up to follow-up visit (Day 18-Day 22)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- D7260C00023
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD 共有時間枠
IPD 共有アクセス基準
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。